Cas:59675-67-1 1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene,2-methyloxirane,oxirane,propane-1,2,3-triol,hydrate manufacturer & supplier

Chemical Name:1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene,2-methyloxirane,oxirane,propane-1,2,3-triol,hydrate

CAS.NO:59675-67-1

Synonyms:1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene,2-methyloxirane,oxirane,propane-1,2,3-triol,hydrate

Molecular Formula:C₂₃H₃₀N₂O₈

Molecular Weight:462.49300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:153.84000

Exact Mass:462.20000

LogP:1.90130

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene,2-methyloxirane,oxirane,propane-1,2,3-triol,hydrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene,2-methyloxirane,oxirane,propane-1,2,3-triol,hydrate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene,2-methyloxirane,oxirane,propane-1,2,3-triol,hydrate Use and application,1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene,2-methyloxirane,oxirane,propane-1,2,3-triol,hydrate technical grade,usp/ep/jp grade.

Related News: Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease. 1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene,2-methyloxirane,oxirane,propane-1,2,3-triol,hydrate manufacturer The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene,2-methyloxirane,oxirane,propane-1,2,3-triol,hydrate supplier Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. 1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene,2-methyloxirane,oxirane,propane-1,2,3-triol,hydrate vendor Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. 1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene,2-methyloxirane,oxirane,propane-1,2,3-triol,hydrate factory Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease.